LABT · Lakewood-Amedex Biotherapeutics Inc.
AI read · Bad for LABT
The AI's read
Nasdaq access matters because losing it could make the shares harder to trade. The company has not yet shown it can meet the listing rule again. Its hearing request pauses suspension, but the panel may reject continued listing. The company also warns that a reverse split may not solve the problem.